Mirum Pharmaceuticals, Inc. (MIRM)
NASDAQ: MIRM · Real-Time Price · USD
43.69
+1.60 (3.80%)
Nov 20, 2024, 4:00 PM EST - Market closed
Mirum Pharmaceuticals Employees
Mirum Pharmaceuticals had 264 employees as of December 31, 2023. The number of employees increased by 68 or 34.69% compared to the previous year.
Employees
264
Change (1Y)
68
Growth (1Y)
34.69%
Revenue / Employee
$1,162,985
Profits / Employee
-$378,072
Market Cap
2.10B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Addus HomeCare | 34,846 |
Evotec SE | 5,061 |
NeoGenomics | 2,100 |
Astrana Health | 1,800 |
GeneDx Holdings | 1,000 |
Supernus Pharmaceuticals | 652 |
Wave Life Sciences | 268 |
Centessa Pharmaceuticals | 76 |
MIRM News
- 7 days ago - Mirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLD's The Liver Meeting - Business Wire
- 8 days ago - Mirum Pharmaceuticals, Inc. (MIRM) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 9 days ago - Mirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update - Business Wire
- 12 days ago - Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 13 days ago - Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences - Business Wire
- 16 days ago - Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024 - Business Wire
- 21 days ago - Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting - Business Wire
- 6 weeks ago - Volixibat Granted Breakthrough Therapy Designation for Cholestatic Pruritus in Primary Biliary Cholangitis - Business Wire